FIELD: medicine, pharmaceutics.
SUBSTANCE: group of invention relates to low molecular weight heparin (LMWH) compositions. Characteristic of the heparin compositions are weight-average molecular weight from 5500 to 8500 Da, anti-IIa activity from 170 to 330 IU/mg, anti-Pa activity from 130 to 190 IU/mg, the anti-IIa/anti-Pa activities ratio being from 2:1 to 1:1 during 30 - 120 minutes after administration to the patient. The heparins composition has improved properties, in particular - those ensuring clinical advantage, such as: action reversibility in response to protamine sulfate, improved anti-Pa activity, relatively stable ratio of anti-IIa/anti-Pa activities in the course of a certain interval of time, a traceable level of activity, bioavailability in case of subcutaneous administration, reduced probability of heparin-induced thrombocytopenia (HIT) development.
EFFECT: thrombotic diseases are prevented and treated using these compositions.
28 cl, 17 dwg, 20 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID PER ORAL MEDICATION, CONTAINING INTENSIFIER | 2007 |
|
RU2437662C2 |
| AGENT WITH ANTICOAGULATING EFFECT AND ITS APPLICATION METHOD | 2021 |
|
RU2799028C2 |
| NON-ANTICOAGULANT GLYCOSAMINOGLYCANS WITH REPEATING DISACCHARIDE UNITS, AND THEIR MEDICAL APPLICATION | 2012 |
|
RU2617764C2 |
| STANDARD DRUG PREPARATIONS AND METHODS OF TREATING THROMBOSIS BY ORAL ADMINISTRATION OF FACTOR XA INHIBITOR | 2007 |
|
RU2452484C2 |
| PURIFIED HEPARIN FRACTION, METHOD OF ITS PREPARING AND PHARMACEUTICAL COMPOSITION CONTAINING ON SAID | 1994 |
|
RU2133253C1 |
| METHODS FOR TREATMENT OF COAGULOPATHIES WITH APPLICATION OF SULPHATED POLYSACCHARIDES | 2005 |
|
RU2347574C2 |
| DERIVATIVES OF POLYSACCHARIDES WITH HIGH THROMOBITIC ACTIVITY IN PLASMA | 2004 |
|
RU2361881C2 |
| METHOD OF OBTAINING LOW-MOLECULAR HEPARIN | 2012 |
|
RU2512768C1 |
| BIOSYNTHETIC HEPARIN | 2017 |
|
RU2760706C2 |
| HEPARIN OF AVERAGE MOLECULAR WEIGHT | 2000 |
|
RU2322245C2 |
